Group 1 - The company announced the acquisition of a 67.5% stake in Chongqing Milan Baiyu Time Plastic Surgery Hospital for a cash consideration of 92.475 million yuan [1] - The company plans to relinquish its preferential purchase rights for a 35% stake in Nanjing Huamei Beauty Hospital [1] - Chongqing Time is a specialized medical beauty service provider with a total operating area of 5,600 square meters [1]

在内生+外延的双重驱动下，朗姿股份(002612)进一步加快了泛时尚产业布局速度，并推动朗姿医疗美 容业务的全国布局。 9月10日晚间，朗姿股份发布公告，拟斥资近亿元收购重庆米兰柏羽时光整形美容医院有限公司（下 称"重庆米兰柏羽"）控股权，上市公司医美业务盈利能力有望得到进一步优化与改善，且医美业务资产 规模、收入规模和利润规模将持续增加。 标的未来三年净利不低于3101万元 9月10日，朗姿股份下属全资子公司北京朗姿医疗管理有限公司（以下简称"北京朗姿医管"）与芜湖博 恒二号创业投资合伙企业（有限合伙）（下称"博恒二号"）签署了《股权转让协议》，北京朗姿医管拟 以现金方式收购博恒二号持有的重庆米兰柏羽67.50%的控股权。 根据资产评估报告显示，截至2025年3月31日，在采用收益法评估后，重庆米兰柏羽100%股权评估值结 果为1.37亿元。基于以上评估结果，经交易双方协商一致，重庆米兰柏羽67.50%股权的转让价格为 9247.50万元。此次股权转让完成后，北京朗姿医管将持有重庆米兰柏羽67.5%控股权，后者将纳入上市 公司合并报表范围。 据悉，重庆米兰柏羽是一家专业从事医疗美容服务，总营业面积达5600 ...

Group 1 - The core point of the article is that Langzi Co., Ltd. is acquiring a 67.50% stake in Chongqing Milan Baiyu Time Aesthetic Medical Hospital for a cash consideration of 92.475 million yuan, which is part of the company's strategy to enhance its presence in the aesthetic medical industry [1][2] - The acquisition is aimed at accelerating the company's dual-driven strategy of both organic growth and external expansion in the fashion industry, thereby increasing the scale and competitiveness of its aesthetic medical business [2] - Following the completion of the transaction, Chongqing Time will become a subsidiary of the company, which is expected to improve the profitability of its aesthetic medical business and increase the asset, revenue, and profit scale of this segment [2] Group 2 - Chongqing Time is a specialized aesthetic medical service provider with a total operating area of 5,600 square meters, located in a prime area of Chongqing, which is popular among young people [1] - The hospital is equipped with advanced facilities, including two thousand-level laminar flow operating rooms, two ten-thousand-level laminar flow operating rooms, and various treatment rooms for skin and dental care [1] - The company aims to provide high-quality, comprehensive, and refined aesthetic medical services in accordance with international standards [1]

证券之星消息，9月10日医疗美容板块较上一交易日下跌1.32%，华熙生物领跌。当日上证指数报收于 3812.22，上涨0.13%。深证成指报收于12557.68，上涨0.38%。医疗美容板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 832982 | 锦波生物 | 307.89 | 1.18% | 1.06万 | 3.27 乙 | | 000615 | *ST美谷 | 3.14 | 0.96% | 6.79万 | 2130.80万 | | 300896 | 爱美客 | 194.95 | -1.25% | 2.82万 | 5.53亿 | | 688363 | 华熙生物 | 59.00 | -1.62% | 4.36万 | 2.58亿 | 从资金流向上来看，当日医疗美容板块主力资金净流出3664.2万元，游资资金净流入3197.38万元，散户 资金净流入466.82万元。医疗美容板块个股资金流向见下表： | 代码 | | | 名称 | | | | | --- | --- | - ...

Core Viewpoint - The article announces the Third China Plastic Surgery Innovation and Transformation Competition, inviting innovative medical beauty projects from the central region to participate, aiming to discover and cultivate potential innovative enterprises and research teams in the medical beauty industry [1][2]. Group 1: Competition Details - The competition is themed "Technology Leads Plastic Surgery, Innovation Drives the Future" and is organized by Beijing Ba Da Chu Plastic Surgery Medical Technology Group and Zhongguancun Medical Device Park [2]. - The central competition area includes Beijing, Tianjin, Hebei, Henan, Shanxi, and other unregistered projects from different regions, with a registration deadline of September 20, 2025 [3][2]. - The competition will provide opportunities for participants to engage with top industry experts and receive various support, including financial incentives, research resources, and market access [9]. Group 2: Evaluation and Awards - The evaluation committee consists of clinical experts (60%) and transformation experts (40%), with a total of 10-15 judges [14]. - The awards include a first prize of 50,000 yuan, second prize of 20,000 yuan, and third prize of 10,000 yuan, along with service packages for concept validation and animal testing [13]. - The evaluation criteria focus on innovation, technical feasibility, market potential, team capability, and transformation potential, with varying weightings assigned to each dimension [14]. Group 3: Participation Criteria - Eligible participants include medical institutions, universities, research institutions, and teams planning to establish innovative enterprises in the medical beauty field [9][10]. - Projects must be related to plastic surgery, medical beauty, biomedicine, medical devices, diagnostic reagents, or medical services, with clear intellectual property rights and significant innovation [10]. Group 4: Support Services - The Ba Da Chu Plastic Surgery Medical Concept Validation Center offers a comprehensive service platform for technology transfer, providing support from concept incubation to product launch, including technical support, compliance, and intellectual property management [15].

Group 1 - The medical beauty sector experienced a rise of 3.39% on September 5, with Ai Meike leading the gains [1] - The Shanghai Composite Index closed at 3812.51, up 1.24%, while the Shenzhen Component Index closed at 12590.56, up 3.89% [1] - Major stocks in the medical beauty sector showed varied performance, with Ai Meike closing at 190.83, up 3.67%, and Huaxi Biological closing at 57.14, up 3.23% [1] Group 2 - The medical beauty sector saw a net inflow of 36.38 million yuan from institutional investors, while retail investors experienced a net outflow of 44.71 million yuan [1] - The trading volume for Ai Meike was 45,900 hands, with a transaction amount of 858 million yuan [1] - The stock performance of other companies in the sector included *ST Meigu, which closed at 3.17, up 0.63%, and Jinbo Biological, which closed at 302.39, down 0.86% [1]

Group 1 - The company Sichuan Milan Baiyu Medical Beauty Hospital, a subsidiary of Langzi Co., is required to pay a total of 22.27 million yuan in taxes, including 16.53 million yuan in income tax and 5.74 million yuan in value-added tax and additional taxes for the years 2021 to 2023 [2] - The company plans to comply with tax regulations and pay the required taxes and penalties while also seeking to protect its legal rights under national tax laws [2] - The tax payment will impact the company's financials, reducing the net profit attributable to shareholders by approximately 30.82 million yuan in 2025, although it will not affect the normal operations of the company significantly [3]

证券日报网讯 9月4日晚间，朗姿股份发布公告称，2025年9月4日，公司全子公司四川米兰柏羽医学美 容医院有限公司（简称"四川米兰"）收到国家税务总局成都市税务局稽查局发来的《税务处理决定书》 （成税稽处〔2025〕55号），四川米兰需补缴2021年-2023年所得税1，653.14万元，增值税及附加税 573.95万元，合计2，227.09万元。四川米兰将按照国家税法的相关规定缴纳上述税款及滞纳金或者提供 相应的担保，但同时也拟将依据国家税法的相关规定，切实维护自身合法权益。 （编辑 任世碧） ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [6][15]. Core Views - The company is undergoing a transformation towards efficiency-oriented brand communication, which has led to revenue growth pressure but improved profitability. Revenue projections for 2025-2027 are estimated at 45.65 billion, 50.31 billion, and 57.10 billion yuan, with corresponding growth rates of -15.0%, 10.2%, and 13.5%. Net profit attributable to shareholders is expected to be 4.63 billion, 5.67 billion, and 6.46 billion yuan, with growth rates of 165.5%, 22.6%, and 13.9% respectively. Earnings per share (EPS) are projected at 0.96, 1.18, and 1.34 yuan per share [4][15]. Summary by Sections Financial Performance - In the first half of 2025, the company reported revenue of 22.61 billion yuan (down 19.6% year-on-year) and a net profit of 2.21 billion yuan (down 35.4% year-on-year). In Q2 2025, revenue was 11.83 billion yuan (down 18.4% year-on-year), while net profit was 1.19 billion yuan (up 20.9% year-on-year) [12][13]. Business Strategy - The company’s management has returned to frontline operations for systematic adjustments, focusing on restructuring brand communication and prioritizing efficiency. In Q2 2025, the sales expense ratio decreased by 12.46 percentage points. The company is concentrating on high-barrier technology asset transformation and enhancing its consumer goods business advantages [13][14]. Medical Business - The medical terminal business generated revenue of 6.73 billion yuan in the first half of 2025, with skin-related medical product revenue at 4.67 billion yuan (down 1.8% year-on-year). The company launched compliant water-light products and strengthened its one-stop anti-aging solutions. The direct sales channel accounts for over 80% of the revenue, and the company is optimizing its product structure and channel layout [14]. Profitability Forecast - The company is expected to face revenue growth challenges but improve profitability. The projected revenue for 2025-2027 is 45.65 billion, 50.31 billion, and 57.10 billion yuan, with net profits of 4.63 billion, 5.67 billion, and 6.46 billion yuan respectively. The EPS is forecasted to be 0.96, 1.18, and 1.34 yuan per share [15][16].

Market Overview - The medical beauty sector experienced a decline of 1.3% on September 4, with Jinbo Biological leading the drop [1] - The Shanghai Composite Index closed at 3765.88, down 1.25%, while the Shenzhen Component Index closed at 12118.7, down 2.83% [1] Individual Stock Performance - ST Meigu closed at 3.15, with a slight increase of 0.32% and a trading volume of 95,700 shares, amounting to a transaction value of 30.34 million yuan [1] - Huaxi Biological closed at 55.35, down 0.66%, with a trading volume of 46,700 shares and a transaction value of 25.9 million yuan [1] - Aimeike closed at 184.07, down 1.83%, with a trading volume of 41,200 shares and a transaction value of 763 million yuan [1] - Jinbo Biological closed at 305.00, down 3.81%, with a trading volume of 9,732.97 shares and a transaction value of 301 million yuan [1] Capital Flow Analysis - The medical beauty sector saw a net outflow of 58.64 million yuan from institutional investors, while retail investors had a net inflow of 24.48 million yuan [1] - The overall capital flow indicates a mixed sentiment, with retail investors showing some interest despite the institutional outflow [1]